HER2 classification in breast cancer cells: A new explainable machine learning application for immunohistochemistry

被引:10
|
作者
Cordova, Claudio [1 ,2 ]
Munoz, Roberto [2 ,3 ]
Olivares, Rodrigo [3 ,4 ]
Minonzio, Jean-Gabriel [2 ,3 ,4 ,5 ]
Lozano, Carlo [6 ]
Gonzalez, Paulina [6 ,7 ]
Marchant, Ivanny [8 ]
Gonzalez-Arriagada, Wilfredo [9 ,10 ]
Olivero, Pablo [1 ,2 ]
机构
[1] Univ Valparaiso, Fac Med, Cell Funct & Struct Lab EFC Lab, 2664 Hontaneda, Valparaiso 2341386, Chile
[2] Univ Valparaiso, Fac Engn, PhD Program Hlth Sci & Engn, Valparaiso 2362735, Chile
[3] Univ Valparaiso, Fac Engn, Sch Informat Engn, Valparaiso 2362735, Chile
[4] Univ Valparaiso, Fac Engn, Ctr Res & Dev Hlth Engn, Valparaiso 2362735, Chile
[5] Univ Valparaiso, Fac Engn, Millennium Inst Intelligent Healthcare iHEALTH, Valparaiso 2362735, Chile
[6] Carlos Van Buren Hosp, Pathol Anat Serv, Valparaiso 2340105, Chile
[7] Andres Bello Natl Univ UNAB, Sch Med Technol, Vina Del Mar 2520000, Chile
[8] Univ Valparaiso, Fac Med, Med Modeling Lab, Valparaiso 2362735, Chile
[9] Univ Los Andes, Fac Dent, Santiago 7620086, Chile
[10] Univ Los Andes, Biomed Res & Innovat Ctr CIIB, Santiago 7620086, Chile
关键词
breast cancer; HER2; IHC; ML; SHAP; RECEPTOR; EXPRESSION; WOMEN; CONSENSUS;
D O I
10.3892/ol.2022.13630
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The immunohistochemical (IHC) evaluation of epidermal growth factor 2 (HER2) for the diagnosis of breast cancer is still qualitative with a high degree of inter-observer variability, and thus requires the incorporation of complementary techniques such as fluorescent in situ hybridization (FISH) to resolve the diagnosis. Implementing automatic algorithms to classify IHC biomarkers is crucial for typifying the tumor and deciding on therapy for each patient with better performance. The present study aims to demonstrate that, using an explainable Machine Learning (ML) model for the classification of HER2 photomicrographs, it is possible to determine criteria to improve the value of IHC analysis. We trained a logistic regression-based supervised ML model with 393 IHC microscopy images from 131 patients, to discriminate between upregulated and normal expression of the HER2 protein. Pathologists' diagnoses (IHC only) vs. the final diagnosis complemented with FISH (IHC + FISH) were used as training outputs. Basic performance metrics and receiver operating characteristic curve analysis were used together with an explainability algorithm based on Shapley Additive exPlanations (SHAP) values to understand training differences. The model could discriminate amplified IHC from normal expression with better performance when the training output was the IHC + FISH final diagnosis (IHC vs. IHC + FISH: area under the curve, 0.94 vs. 0.81). This may be explained by the increased analytical impact of the membrane distribution criteria over the global intensity of the signal, according to SHAP value interpretation. The classification model improved its performance when the training input was the final diagnosis, downplaying the weighting of the intensity of the IHC signal, suggesting that to improve pathological diagnosis before FISH consultation, it is necessary to emphasize subcellular patterns of staining.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Impact of the Change of the Criteria for HER2 Immunohistochemistry Interpretation on HER2 Status in Breast Cancer
    Harada, Shuko
    Shen, Dejun
    Wei, Shi
    MODERN PATHOLOGY, 2016, 29 : 44A - 44A
  • [2] Impact of the Change of the Criteria for HER2 Immunohistochemistry Interpretation on HER2 Status in Breast Cancer
    Harada, Shuko
    Shen, Dejun
    Wei, Shi
    LABORATORY INVESTIGATION, 2016, 96 : 44A - 44A
  • [3] Using Machine Learning to Predict Final HER2 Status in Invasive Breast Cancer Cases that are Equivocal (2+) by Immunohistochemistry
    Rasmussen, Sean
    Taylor, Valerie
    Surette, Alexi
    Barnes, Penny
    Bethune, Gillian
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 182 - 182
  • [4] Using Machine Learning to Predict Final HER2 Status in Invasive Breast Cancer Cases that are Equivocal (2+) by Immunohistochemistry
    Rasmussen, Sean
    Taylor, Valerie
    Surette, Alexi
    Barnes, Penny
    Bethune, Gillian
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 182 - 182
  • [5] Standardized Assessment of the HER2 Status in Breast Cancer by Immunohistochemistry
    Hicks, David G.
    LABMEDICINE, 2011, 42 (08): : 459 - 467
  • [6] HER2 intratumoural heterogeneity in breast cancer: Proposal of a new classification
    Nitta, H.
    Li, Z.
    Reis-Filho, J.
    Sotiriou, C.
    Chenard, M. P.
    Nielsen, S.
    Viale, G.
    Sapino, A.
    Tot, T.
    VIRCHOWS ARCHIV, 2017, 471 : S24 - S24
  • [7] Correlation Between Machine Learning-based Characterization of HER2 Protein Expression by Immunohistochemistry and Response to Neoadjuvant Treatment in HER2+Breast Cancer
    Kurt, Busem Binboga
    Kirkup, Christian
    Ogayo, Esther Ritah
    Krause, Emma
    Cramer, Harry
    Degryse, Sandrine
    Hennek, Stephanie
    Rahman, Tasnim
    Tarantino, Paolo
    Chambre, Laura
    Trotter, Ben
    Hipp, Jennifer
    Drage, Michael
    Tolaney, Sara
    Schnitt, Stuart
    Waks, Adrienne
    Mittendorf, Elizabeth
    LABORATORY INVESTIGATION, 2024, 104 (03) : S121 - S123
  • [8] Standardization of HER2 Immunohistochemistry in Breast Cancer by Automated Quantitative Analysis
    Gustavson, Mark D.
    Bourke-Martin, Brian
    Reilly, Dylan
    Cregger, Melissa
    Williams, Christine
    Mayotte, Jane
    Zerkowski, Maciej
    Tedeschi, Greg
    Pinard, Robert
    Christiansen, Jason
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2009, 133 (09) : 1413 - 1419
  • [9] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Meisel, Jane
    Suo, Aili
    Zhang, Chao
    Wei, Zhimin
    Aneja, Ritu
    Li, Zaibo
    Nahta, Rita
    Li, Xiaoxian
    MODERN PATHOLOGY, 2019, 32
  • [10] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Zhang, Chao
    Suo, Aili
    Shi, Qiuying
    Wei, Zhimin
    Li, Zaibo
    Krishnamurti, Uma
    Li, Xiaoxian
    MODERN PATHOLOGY, 2019, 32